PRM12 Joint Estimation of Progression Free Survival and Overall Survival

Joint Modeling of Progression-free Survival and Overall Survival by a Bayesian NICE Model

Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate

Objective Atypical meningioma is rare tumor and there is no accurate guide line for optimal treatment. This retrospective study analyzed the prognostic factors, the effect of different methods of treatments and the behavior of atypical meningioma. Methods Thirty six patients were diagnosed as atypical meningioma, among 273 patients who were given a diagnosis of meningioma in the period of 200...

Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

The standard phase II trial design has changed dramatically over the past decade. Randomized phase II studies have essentially become the standard phase II design in oncology for a variety of reasons. The use of these designs is motivated by concerns about the use of historical data to determine if a new agent or regimen shows promise of activity. However, randomized phase II designs come with ...

Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor.

PURPOSE Gastrointestinal stromal tumor (GIST) is a relatively rare tumor that is treated with targeted therapies in advanced stages. Randomized clinical trials (RCT) often require long follow-up and large sample sizes to evaluate overall survival (OS), the gold-standard measure of treatment efficacy. However, changes in therapy following disease progression may complicate survival assessments. ...

Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

BACKGROUND The use of auxiliary endpoints may provide efficiencies for clinical trial design, but such endpoints may not have intrinsic clinical relevance or clear linkage to more meaningful endpoints. The purpose of this study was to generate a novel endpoint that considers both overall survival (OS) and earlier events such as progression-free survival (PFS) and determine whether such an endpo...